A
Alessandro Serretti
Researcher at University of Bologna
Publications - 817
Citations - 35088
Alessandro Serretti is an academic researcher from University of Bologna. The author has contributed to research in topics: Bipolar disorder & Major depressive disorder. The author has an hindex of 81, co-authored 711 publications receiving 30197 citations. Previous affiliations of Alessandro Serretti include University of Sassari & Vita-Salute San Raffaele University.
Papers
More filters
Journal ArticleDOI
Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study.
Markus Dold,Lucie Bartova,Daniel Souery,Julien Mendlewicz,Alessandro Serretti,S. Porcelli,Joseph Zohar,Stuart Montgomery,Siegfried Kasper +8 more
TL;DR: The findings suggest that the various anxiety disorders subtypes display divergent clinical characteristics and are associated with different variables, especially comorbid GAD appears to be characterized by high symptom severity and poor treatment response.
Journal ArticleDOI
The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression.
Alexander Kautzky,Pia Baldinger,Daniel Souery,Stuart Montgomery,Julien Mendlewicz,Joseph Zohar,Alessandro Serretti,Rupert Lanzenberger,Siegfried Kasper +8 more
TL;DR: The random forests prediction model for treatment outcome showed that combining clinical and genetic variables gradually increased the prediction performance recognizing correctly 25% of responders using all 4 factors, and furthermore shows the strength of an interaction-based model combining statistical algorithms in identifying and operating treatment predictors.
Journal ArticleDOI
Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders.
Alessandro Serretti,Cristina Cusin,David Rossini,Paola Artioli,Danilo Dotoli,Raffaella Zanardi +5 more
TL;DR: The present independent replication confirms SERTPR variants as a liability factor for antidepressant efficacy while the TPH effect is not unequivocal.
Journal ArticleDOI
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.
Filippo Corponi,Chiara Fabbri,István Bitter,Stuart Montgomery,Eduard Vieta,Siegfried Kasper,Stefano Pallanti,Alessandro Serretti +7 more
TL;DR: These new antipsychotics were developed with the aim of improving efficacy on negative and depressive symptoms and reducing metabolic and cardiovascular side effects compared to prior SGAs, while keeping the risk of extrapyramidal symptoms low.
Journal ArticleDOI
Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine
TL;DR: It was shown that tapering methadone to low doses before entering the pharmacologically assisted discontinuation phase was clinically acceptable in detoxification from long-term methadon treatment.